Univariate Analyses of Potential Prognostic Variables
| Variable . | Category . | DFS . | Survival . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N . | Median (yr) . | Probability of CCR at 5 yr (95% CI) . | P . | N . | Median (yr) . | Probability of Survival at 5 yr (95% CI) . | P . | ||
| Age | <60 | 181 | 1.5 | .35 (.27-.44) | .03 | 214 | 2.1 | .35 (.28-.43) | <.001 |
| ≥60 | 23 | 1.1 | .13 (.05-.32) | 42 | 0.2 | .09 (.03-.22) | |||
| Continuous | 204 | <.001 | 256 | <.001 | |||||
| WBC count | <30,000 | 130 | 2.3 | .40 (.30-.51) | <.001 | 155 | 2.4 | .37 (.28-.47) | .001 |
| ≥30,000 | 73 | 0.8 | .18 (.10-.31) | 100 | 1.1 | .21 (.13-.32) | |||
| Log WBC count | 203 | <.001 | 255 | <.001 | |||||
| Mediastinal mass | Present | 20 | >5.7 | .75 (.51-.89) | <.001 | 23 | >5.7 | .70 (.48-.85) | <.001 |
| Absent | 180 | 1.3 | .28 (.20-.37) | 229 | 1.8 | .27 (.20-.35) | |||
| FAB | L1 | 79 | 1.9 | .37 (.25-.50) | .12 | 99 | 2.2 | .36 (.25-.47) | .11 |
| L2 | 110 | 1.1 | .29 (.15-.41) | 134 | 1.4 | .27 (.18-.37) | |||
| Immunophenotype | T/TMy | 39 | >3.8 | .56 (.38-.73) | .01 | 48 | >3.2 | .50 (.34-.65) | .004 |
| B/BMy | 126 | 1.3 | .27 (.17-.38) | 159 | 1.5 | .26 (.18-.36) | |||
| Cytogenetic group4-150 | Normal | 65 | 2.3 | .38 (.26-.53) | <.001 | 79 | 2.9 | .37 (.26-.50) | <.001 |
| Miscellaneous | 64 | 4.1 | .52 (.37-.67) | 82 | 3.0 | .49 (.35-.62) | |||
| Unfavorable | 75 | 0.8 | .11 (.04-.25) | 95 | 1.2 | .12 (.06-.25) | |||
| Treatment protocol | 8811, 9111, 9311 | 162 | 1.7 | .35 (.26-.45) | .06 | 189 | 1.9 | .35 (.27-.44) | .06 |
| 8011, 8411, 8513 | 42 | 0.9 | .21 (.11-.37) | 67 | 1.7 | .19 (.11-.30) | |||
| Variable . | Category . | DFS . | Survival . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N . | Median (yr) . | Probability of CCR at 5 yr (95% CI) . | P . | N . | Median (yr) . | Probability of Survival at 5 yr (95% CI) . | P . | ||
| Age | <60 | 181 | 1.5 | .35 (.27-.44) | .03 | 214 | 2.1 | .35 (.28-.43) | <.001 |
| ≥60 | 23 | 1.1 | .13 (.05-.32) | 42 | 0.2 | .09 (.03-.22) | |||
| Continuous | 204 | <.001 | 256 | <.001 | |||||
| WBC count | <30,000 | 130 | 2.3 | .40 (.30-.51) | <.001 | 155 | 2.4 | .37 (.28-.47) | .001 |
| ≥30,000 | 73 | 0.8 | .18 (.10-.31) | 100 | 1.1 | .21 (.13-.32) | |||
| Log WBC count | 203 | <.001 | 255 | <.001 | |||||
| Mediastinal mass | Present | 20 | >5.7 | .75 (.51-.89) | <.001 | 23 | >5.7 | .70 (.48-.85) | <.001 |
| Absent | 180 | 1.3 | .28 (.20-.37) | 229 | 1.8 | .27 (.20-.35) | |||
| FAB | L1 | 79 | 1.9 | .37 (.25-.50) | .12 | 99 | 2.2 | .36 (.25-.47) | .11 |
| L2 | 110 | 1.1 | .29 (.15-.41) | 134 | 1.4 | .27 (.18-.37) | |||
| Immunophenotype | T/TMy | 39 | >3.8 | .56 (.38-.73) | .01 | 48 | >3.2 | .50 (.34-.65) | .004 |
| B/BMy | 126 | 1.3 | .27 (.17-.38) | 159 | 1.5 | .26 (.18-.36) | |||
| Cytogenetic group4-150 | Normal | 65 | 2.3 | .38 (.26-.53) | <.001 | 79 | 2.9 | .37 (.26-.50) | <.001 |
| Miscellaneous | 64 | 4.1 | .52 (.37-.67) | 82 | 3.0 | .49 (.35-.62) | |||
| Unfavorable | 75 | 0.8 | .11 (.04-.25) | 95 | 1.2 | .12 (.06-.25) | |||
| Treatment protocol | 8811, 9111, 9311 | 162 | 1.7 | .35 (.26-.45) | .06 | 189 | 1.9 | .35 (.27-.44) | .06 |
| 8011, 8411, 8513 | 42 | 0.9 | .21 (.11-.37) | 67 | 1.7 | .19 (.11-.30) | |||
Abbreviations: CI, confidence interval; FAB, French-American-British classification; N, number of patients.
Unfavorable consists of patients with t(9;22), t(4;11), −7, or +8 abnormalities; miscellaneous group consists of all other abnormalities.